The approval of the niraparib/abiraterone dual-action tablet for BRCA-positive mCRPC is based on findings from the phase 3 MAGNITUDE study.
Closing out their discussion on how treatment and management of advanced prostate cancer affects their clinical practice, expert urologists consider how the therapeutic landscape continues to evolve and look toward future evolutions in care.
The rationale for utilizing fluoroscopic imaging as well as other evolving technologies that are currently being developed and explored in urology.
In this column, the authors discuss how the coronavirus disease 2019 (COVID-19) shutdown yielded unexpected opportunities in urologic research.
“These results further support the importance of screening for germline and somatic BRCA1/2 alterations to deliver more precise care for our patient," says David Olmos, MD, PhD.
Social Security benefits aren’t sufficient to fund retirement for most people. And given the aging of the population and projected trust-fund shortfall, they may be less generous in the future.
Perioperative treatment with cabozantinib is feasible with early signs of clinical activity in patients with intermediate- and poor-risk metastatic renal cell carcinoma.
“As other factors such as access to care, socioeconomic conditions, patient preference, and other unknown confounders might have played a role in the observed disparity, it is still unclear whether overestimating the postoperative eGFR of Black patients contributes to the lower use of nephron-sparing approaches in this population,” the authors write.
"The good news is that women have been entering medicine in increasing numbers for more than three decades. The not-so-good news is that women are still underrepresented and underutilized in positions of power," writes Deborah M. Shlian, MD, MBA.
In this companion article, Armine K. Smith, MD, reflects on the role of kidney-sparing approaches for LG UTUC and emphasizes the importance of patient-provider communication when making treatment decisions.
Ransomware has never been a more serious threat for health care organizations, even small medical practices.
Closing out their discussion on how treatment and management of advanced prostate cancer affects their clinical practice, expert urologists consider how the therapeutic landscape continues to evolve and look toward future evolutions in care.
A nurse practitioner discusses how she supports multiple providers in a large academic practice.
Learning curve for technique is short, but capital expenditures are required.
"We need health systems, state medical boards and physician employment settings to commit to prioritizing physician wellbeing and provide the reassurances and resources that encourage physicians in need to seek help," writes Russell Libby, MD.
Although traditional payment and communication methods remain relevant, the survey highlights a paradigm shift in patients' billing expectations overall.
A recap of presentations from AUA 2021 highlighting next steps using novel therapies as combination approaches to treat advanced prostate cancer.
“These findings provide encouraging evidence that immune checkpoint inhibitors can be effective in treating a subset of patients with penile squamous cell carcinoma," said co-first author Amin Nassar, a clinical fellow at Yale School of Medicine.
Dr Raoul Concepcion leads a multidisciplinary expert panel in a discussion about the challenges of long-term follow-up of prostate cancer in patients with negative bone/CT but positive molecular indicators of recurrence.
“MRI-based screening showed lower proportions of screening-positive cases, lower false positive rates, and higher PPVs [positive predictive values] than those of PSA-based screening,” noted Taek Min Kim, MD.
The Cures Act has teeth and consumers are becoming increasingly aware of their right to obtain their information.
Moffitt Cancer Center conducted the first prospective study to investigate genomic biomarkers associated with aggressive disease in African American men with prostate cancer
"The emulation framework lends the design and conduct of observational analyses some of the rigor required for the planning of a randomized trial. In doing so, it provides an innovative and principled approach to improve the evidence base on the comparative effectiveness of interventions," writes Boris Gershman, MD, and Aaron Fleishman, MPH.
The findings of harassment and inappropriate behavior come at a time when there is widespread agreement among health care leaders about the need for a more diverse physician workforce.
Urologists offer their perspectives on toxicity seen in patients with prostate cancer who are undergoing radiation treatment.
"As more patients become interested in remote patient monitoring and case studies continue to show improved patient outcomes, practices must seek ways to integrate these tools into their workflows," writes Lucienne Marie Ide, MD, PhD.
Dr Jason Hafron concludes his discussion of mCSPC by highlighting the need to work towards a cure for the disease, and two major clinical trials investigating triplet treatment regimens.
Treatments provide a targeted therapeutic strategy for metastatic castration-resistant prostate cancer.
CCM programs can engage multiple providers to care for patients while reducing in-person visits.